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Abstract
In HIV-seronegative patients with advanced Hodgkin lymphoma (HL), Epstein–Barr virus (EBV) viraemia at diagnosis 
predicts a worse progression-free survival (PFS), independent of the International Prognostic Score. However, its role in 
HIV-associated HL is uncharacterised. We collected clinico-pathologic and treatment data from a prospective series of 44 
HIV-associated HLs from 2000 to 2016. We evaluated circulating EBV DNA as a prognostic factor on uni- and multivari-
able analyses in relationship to the International Prognostic Index criteria. In 44 patients with HIV-associated HL, EBV 
was detected by in situ hybridisation in all diagnostic biopsies. Blood EBV DNA was detectable in 26 patients (59%) with 
a median of 600 copies/mL (range 0–161,000). EBV DNA was independent of CD4 cell count (p = 0.9) or HIV viral load 
(p = 0.6) and did not predict PFS (HR 1.6, 95% CI 0.39–6.7, p = 0.49). EBV DNA is not a prognostic trait in HIV-associated 
HL. Prognostication in HIV-associated HL should be solely based on the International Prognostic Index criteria.
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Introduction
Hodgkin lymphoma (HL) is a neoplasm arising from ger-
minal centre or post-germinal centre B lymphocytes. It 
is characterised by the presence of malignant Hodgkin/
Reed–Sternberg (HRS) cells in the backdrop of an inflam-
matory infiltrate. Studies have demonstrated an increased 
incidence of HL in immunosuppressed populations, in par-
ticular people living with HIV (PLWH) [1]. Studies have 
found the incidence of HL in the HIV-infected population 
to be 15–17 times higher than compared in the age- and 
gender-matched general population [2, 3]. Furthermore, the 
incidence of HL in PLWH has increased since the introduc-
tion of combination antiretroviral therapy (cART) [4]. HL 
in immunosuppressed populations is almost always associ-
ated with the gamma herpesvirus Epstein–Barr virus (EBV) 
[5, 6]. Although early studies suggested that HL was more 
aggressive in PLWH and carried a poor prognosis [7], more 
recent studies have found no difference in clinical outcomes 
when PLWH are treated with cART and the same chemo-
therapy regimens as the general population with HL [8].
The International Prognostic Score (IPS) is a widely used 
risk stratification tool for advanced HL that was created by 
the International Prognostic Factor Project on Advanced 
Hodgkin’s Disease in 1998 [9]. It comprises seven param-
eters that are independently associated with a poorer clini-
cal outcome: serum albumin less than 40 g/L, haemoglobin 
less than 105 g/L, male gender, age over 45 years, stage IV 
disease, white blood cell count ≥ 15,000/microL, and lym-
phocyte count less than 600/microL and/or less than 8 per 
cent of the white blood cell count.
A recent study in HIV-seronegative patients with 
advanced stage HL found that blood EBV DNA also pre-
dicted clinical outcomes [10]. Moreover, patients with 
detectable blood EBV DNA at HL diagnosis had a worse 
disease-free survival, independent of the IPS [10]. In this 
study, we examine the plasma EBV DNA detectability in 
HIV-positive patients with advanced HL and evaluate its 
prognostic value.
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Materials and methods
At the National Centre for HIV malignancies at the Chel-
sea and Westminster Hospital, we prospectively collect 
routine data on all individuals who attend including all 
HIV-seropositive patients diagnosed with lymphoma 
since 1986. Data on patient characteristics, prognostic 
factors, treatment and outcomes for patients diagnosed 
with advanced HL since 2000 was extracted from the data-
base. The study complied with local regulations and was 
approved by the institutional review boards of Chelsea and 
Westminster Hospital. Patient details were anonymised, 
and therefore, patient consent was not required.
Quantitative EBV DNA testing methodologies evolved 
during the study period. The current standard is DNA 
extraction from whole blood samples (MagNA Pure LC 
2.0, Roche) followed by PCR (Rotor-Gene Q, Qiagen) 
using a commercial assay (Artus EBV RG, Qiagen) with 
a limit of detection of 500 copies/mL. The EBV status was 
determined as detected or not detected according to the 
assay available at the time of sampling.
Comparison of variables between the groups was by 
Chi-square test for categorical data and Mann–Whitney or 
Kruskal–Wallis test for nonparametric continuous varia-
bles; all p values are two-sided. The time interval from HL 
diagnosis until death, study censoring or loss to follow-up 
was used to calculate overall survival. Progression-free 
survival was defined as the period of time from HL diag-
nosis to progression, loss to follow-up or death. Survival 
curves were plotted according to the method of Kaplan and 
Meier [11]. The log rank method was used to test for the 
significance of differences in survival distributions [12].
Results
During the 16-year inclusion period (2000–2016), 44 PLWH 
and advanced HL were identified. The mean age at advanced 
HL diagnosis was 42 years (range 21–69), 40 (91%) were 
male, and 79% were established on cART of whom 88% had 
undetectable HIV viral load in plasma. The median CD4 
cell count was 169/mm3 (15-782), and 84% had an IPS > 2.
All diagnoses were confirmed by central review of 
histopathology, and in situ hybridisation of Epstein–Barr 
virus-encoded small RNAs (EBERs) found that EBV was 
present in 100% of diagnostic tissue. However, blood EBV 
DNA at HL diagnosis was detectable in 26 patients (59%) 
and the median EBV DNA at diagnosis was 600 copies/mL 
(range 0–161,000). Detectable blood EBV DNA was not 
associated with the CD4 cell count (p = 0.9) or detectable 
plasma HIV viral load (p = 0.6).
One patient, who had advanced AIDS and active oppor-
tunistic infection (OI) at the time of HL diagnosis, was 
treated with best supportive care only. The remaining 43 
patients were treated with combination chemotherapy with 
curative intent: 41 ABVD (doxorubicin, bleomycin, vin-
blastine, dacarbazine), 1 VEPEB (vinblastine, cyclophos-
phamide, procarbazine, prednisolone, mitoxantrone, bleo-
mycin, etoposide) and 1 ChlVPP (chlorambucil, vinblastine, 
procarbazine, prednisolone). One of these 43 patients died 
in remission of OI and 10 relapsed. All 10 patients with 
relapsed HL were treated with salvage cisplatin-based 
chemotherapy. Two had chemorefractory disease, and both 
died after further lines of salvage chemotherapy. All of the 
remaining 8 patients with relapsed HL are alive in remis-
sion, including 6 who received high-dose chemotherapy and 
autologous stem cell rescue. Thus, in total 4 patients have 
died, 2 from chemorefractory relapsed HL, 1 from untreated 
HL with concomitant OI and 1 from OI in first remission 
of HL.
The median follow-up is 4.5 years (maximum 14 years). 
The 5-year overall survival (OS) for the 44 patients is 95% 
(95% confidence interval 88–100%), and the 5-year progres-
sion-free survival (PFS) is 76% (95% CI 6-092%). Detect-
able EBV did not correlate with any of the seven prognos-
tic parameters that make up the IPS apart from anaemia 
(Hb < 105 g/L, p = 0.02, Table 1). In univariate analysis, 
detectable blood EBV viraemia was not associated with 
Table 1  Details of International Prognostic Score for the cohort of 44 
patients with advanced HIV-associated HL and according to blood 
EBV status
a Values missing for 2 patients
b IPSs at diagnosis missing for 4 patients
IPS component All Detectable 
blood EBV
Undetect-
able blood 
EBV
χ2 test
Male 40/44 14/26 16/18 P = 0.7
Age > 45 years 28/44 15/26 13/18 P = 0.3
Stage IV 36/44 23/26 13/18 P = 0.2
Albumin < 40 g/L 42/42a 26/26 16/16 P = 1
Anaemia
Hb < 105 g/L
23/42a 18/26 5/16 P = 0.02
Leucocytosis
WCC > 15x109/L
0/42a 0/26 0/16 P = 1
Lymphope-
nia < 0.6x109/L
15/42a 10/26 5/16 P = 0.2
IPS  2b 7 (18%) 3 (12%) 4 (25%) P = 0.3
IPS  3b 11 (28%) 6 (25%) 5 (31%)
IPS  4b 7 (18%) 3 (12%) 4 (25%)
IPS  5b 12 (30%) 9 (38%) 3 (19%)
IPS  6b 3 (7%) 3 (12%) 0 (0%)
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progression-free survival (hazard ratio 1.6, 95% CI 0.39–6.7 
log rank p = 0.49, Fig. 1).
Discussion
The pathogenetic link between EBV and HL was suggested 
by epidemiological studies in the late twentieth century [13], 
and this was confirmed by a large Scandinavian population-
based cohort study of young adults with infectious mononu-
cleosis [14]. An elevated risk of HL was also demonstrated 
in immunosuppressed individuals, including allograft recipi-
ents [15] and PLWH [1, 16]. Moreover, HL in the context 
of immunosuppression is almost always associated with 
EBV infection [17, 18]. In these cases, EBV is present in 
the tumour cells of HL where the virus expresses a limited 
repertoire of latent genes including latent membrane pro-
teins (LMP1 and LMP2a) and EBV-encoded small RNAs 
(EBERs) which can be detected by in situ hybridisation.
Quantitative PCR can measure the viral load of EBV 
in blood, and detectable blood EBV correlates closely 
with EBER-ISH in HIV-negative patients with advanced 
stage HL [10, 19, 20]. Analysis of samples from HIV-
negative patients with advanced HL enrolled into a large 
North American Cancer Cooperative Intergroup Trial that 
enrolled 794 patients found EBER-ISH expression in only 
51/315 (16%) of tissue samples available for analysis. Pre-
treatment plasma samples were available for 274 patients, 
and 54 (20%) had detectable plasma EBV viraemia using a 
cut-off of 60 copies/100 µL. For 116 patients, both tissue 
for ISH and pre-treatment plasma samples were available 
and the concordance between tissue and plasma detection of 
EBV was very high at 96%. Despite the high concordance 
in these patients with both samples available, the prognostic 
significance of plasma EBV and tissue EBV-ISH differed. 
The HIV-negative study found that detectable EBV virae-
mia was associated with an inferior failure-free survival 
(p = 0.009), but tissue sample EBER-ISH did not predict 
outcome (p = 0.43). Moreover, pre-treatment detectable 
blood EBV was an independent prognostic variable after 
adjusting for IPS, treatment arm and histological subtype 
[10].
In contrast, in PLWH we found EBV by ISH in all 44 
diagnostic tissue samples and detectable blood EBV in 59%. 
Because of the variation in the quantitative EBV DNA test-
ing methodologies over the study period, direct comparison 
between the EBV viral load results was not undertaken and 
it was not possible to investigate the prognostic value of 
the level of the EBV DNA in the blood. However, analy-
sis using detectable EBV viraemia as a nominal variable 
demonstrated that in PLWH, detectable blood EBV did not 
predict progression-free survival.
The reason for the discrepancy between these two 
findings is not clear. The sample size for the HIV-related 
advance HL is much smaller, and it is noteworthy that all 
tumour samples in PLWH had EBV detected by EBER-
ISH, but this was only found in 16% of the HIV-negative 
series. Another discrepancy between the two studies is the 
concordance between tissue and plasma detection of EBV 
with a very high concordance in the HIV-negative study, 
whilst only 59% of PLWH had EBV viraemia, but all had 
EBV detected in HL tissue biopsies. Another possible con-
founder is the origin of the EBV viraemia. Previous studies 
have confirmed that EBV in HL tissues is latent rather than 
replicative in PLWH [17] and so the EBV viraemia may 
originate from replicative infection of other host cells. Under 
these circumstances, it might be expected that EBV viraemia 
would be higher in more immunosuppressed individuals, but 
there was no correlation between detectable blood EBV and 
CD4 cell count (p = 0.9) or detectable plasma HIV viraemia 
(p = 0.6).
Conclusion
Although EBV is invariably detectable by in situ hybridisa-
tion in HL in PLWH, plasma EBV DNA was only detectable 
in 59% patients with advanced HL. In contrast to findings in 
HIV-negative patients with advanced HL, detectable blood 
EBV DNA did not predict overall or progression-free sur-
vival. Furthermore, it did not add to the prognostic value 
of the IPS.
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